Aptevo Therapeutics, Inc. (APVO)
1.87
-0.01
(-0.53%)
USD |
NASDAQ |
Sep 09, 16:00
1.80
-0.07
(-3.74%)
After-Hours: 18:10
Aptevo Therapeutics Enterprise Value : -2.920M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -2.920M |
| September 04, 2026 | -3.119M |
| September 03, 2026 | -3.162M |
| September 02, 2026 | -1.899M |
| September 01, 2026 | -2.268M |
| August 31, 2026 | -2.126M |
| August 28, 2026 | -2.232M |
| August 27, 2026 | -2.154M |
| August 26, 2026 | -2.168M |
| August 25, 2026 | -2.097M |
| August 24, 2026 | -2.168M |
| August 21, 2026 | -1.785M |
| August 20, 2026 | -1.672M |
| August 19, 2026 | -1.714M |
| August 18, 2026 | -1.473M |
| August 17, 2026 | -1.601M |
| August 14, 2026 | -1.416M |
| August 13, 2026 | -0.7634M |
| August 12, 2026 | -0.6215M |
| August 11, 2026 | 0.281M |
| August 10, 2026 | 0.1164M |
| August 07, 2026 | 0.3434M |
| August 06, 2026 | 0.1873M |
| August 05, 2026 | 0.3576M |
| August 04, 2026 | 0.2157M |
| Date | Value |
|---|---|
| August 03, 2026 | 0.017M |
| July 31, 2026 | 0.2441M |
| July 30, 2026 | 0.2725M |
| July 29, 2026 | 0.0596M |
| July 28, 2026 | 0.386M |
| July 27, 2026 | 0.386M |
| July 24, 2026 | 0.6414M |
| July 23, 2026 | 0.613M |
| July 22, 2026 | 0.7265M |
| July 21, 2026 | 0.684M |
| July 20, 2026 | 1.159M |
| July 17, 2026 | 1.138M |
| July 16, 2026 | 0.7975M |
| July 15, 2026 | 0.8968M |
| July 14, 2026 | 0.9678M |
| July 13, 2026 | 0.3009M |
| July 10, 2026 | 0.0029M |
| July 09, 2026 | 0.0029M |
| July 08, 2026 | 0.7975M |
| July 07, 2026 | 0.8117M |
| July 06, 2026 | 0.7549M |
| July 02, 2026 | 0.7549M |
| July 01, 2026 | 0.7265M |
| June 30, 2026 | 0.7124M |
| June 29, 2026 | -4.626M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.356M |
| Total Expenses (Quarterly) | 6.356M |
| EPS Diluted (Quarterly) | -5.313 |
| Earnings Yield | -3.09K% |
| Normalized Earnings Yield | -3088.92 |